Pharmacokinetics of Methadone in Adults Undergoing Cardiac Surgery With Extracorporeal Circulation

In cardiac surgery, the establishment of Cardiopulmonary bypass (CPB) involves profound changes that can alter the pharmacokinetics and clinical response to drugs. Methadone has characteristics that make it attractive for the management of postoperative pain, however, to date there are no pharmacokinetic or pharmacodynamic studies that allow guidance on how to perform the dosage and dose adjustment of methadone in patients undergoing cardiopulmonary bypass.

The main of this study is to describe the pharmacokinetics of methadone in adult patients undergoing cardiac surgery with extracorporeal circulation.

A pharmacokinetic clinical study will be proposed. Drug concentrations will be measured at different times, estimating how plasma levels vary before, during and after CPB. For the plasma methadone analysis, 10 blood samples will be taken from each patient following a pre-established schedule. They will be analyzed using a high performance liquid chromatography (HPLC) spectrofluorometric method.

Changes in volumes, clearance, and other covariates associated with CPB are not expected to significantly affect methadone plasma concentrations.

Study Overview

• Status: Not yet recruiting
• Conditions: Cardiopulmonary Bypass; Methadone; Cardiosurgery
• Intervention / Treatment: Drug: Methadone

Detailed Description

Introduction:

Pharmacokinetics studies the processes of absorption, distribution, metabolism and excretion of a drug. There are multiple conditions that can affect the expected pharmacokinetic behavior of a drug. In cardiac surgery, for example, most surgeries require stopping the heart. For this, different cardioplegia solutions and an extracorporeal circulation machine (ECC) are used to allow oxygenation and blood circulation to continue to the rest of the body. The establishment of Cardiopulmonary bypass (CPB) involves profound changes that can alter the pharmacokinetics and clinical response to drugs. An adequate knowledge of the magnitude and direction of these changes is therefore necessary for each drug in particular, in order to achieve an optimal dosage at the time of use. In order to optimize postoperative pain management in cardiac surgery, other drugs have been used as an alternative to the usual management of boluses of morphine or fentanyl. Methadone has pharmacokinetic and pharmacodynamic characteristics that make it attractive; however, despite being a relatively old drug, its use in cardiac surgery is relatively recent. To date, few studies have been published with the use of methadone in a single intraoperative bolus scheme, both studies report positive results. However, to date there are no pharmacokinetic or pharmacodynamic studies that provide guidance on how to dose and adjust the dose of methadone in patients undergoing cardiopulmonary bypass in this context.

THEORETICAL FRAMEWORK Pharmacokinetics is the branch of pharmacology that studies the relationship between the dose of a drug and its plasma concentrations, "what the body does to the drug." Pharmacokinetics studies the processes of absorption, distribution, metabolism and excretion of a drug.

Compartment pharmacokinetic models emerge as a way of conceptualizing this study. They describe the organism as a set of compartments where each one represents a part of the biological material in which the drug is supposed to be uniformly distributed and has the same kinetic properties. It is possible to use 1 or more compartments to describe the kinetics of a drug. For the estimation of population parameters, specific study methods are required that allow the most accurate and precise estimation of population parameters, both of fixed effect, as well as of inter and intra-individual random effect. Among the available parametric methods, which assume a known probability distribution, one widely used is the non-linear mixed effects model. Proposed by Sheiner and Beal, it is currently the reference method in pharmacokinetic analysis in large population groups. This method allows estimating inter individual variability without ignoring the large number of limitations present in observational data.

From a clinical perspective, there are multiple conditions that can alter the expected pharmacokinetic behavior of a drug; diseases, for example, can modify the physiological functions of different organs, alter blood flow and alter the metabolism and elimination of some drugs. Another example is the case of cardiac surgery where, for the realization of most of the surgeries it is required to stop the heart. For this, different cardioplegia solutions and an extracorporeal circulation machine (CPB) are used to allow oxygenation and blood circulation to continue to the rest of the body during the surgical procedure. The establishment of CPB involves profound changes that can alter the pharmacokinetics and clinical response to drugs. An adequate knowledge of the magnitude and direction of these changes is therefore necessary for each drug in particular, in order to achieve an optimal dosage at the time of use.

At the start of CPB, acute hemodilution can cause a decrease in the plasma concentration of almost any drug. Hypothermia, frequently used in cardiac surgery, can also reduce metabolic activity in the liver and thus decrease metabolic clearance. The oxygenator membrane, reservoir filters, and ECC circuit can sequester varying amounts of some drugs. This occurs with fentanyl, for which a 25% decrease in plasma concentration upon entering CPB was initially described. A similar effect was described for sulfentanil. In the case of remifentanil that is metabolized by plasma esterases, a decrease in clearance is observed with hypothermia (6.3% per 1ºC). In this context, it has not been described how the pharmacokinetics of methadone could change in these patients.

Methadone is a synthetic opioid that has pharmacokinetic and pharmacodynamic characteristics that make it attractive for its perioperative use, both in acute pain and in chronic pain. Its long half-life allows more stable inter-dose plasma levels. Administered in a single dose of 0.2 to 0.3 mg / kg, it has not been associated with a higher incidence of adverse effects (compared to short-acting opioids), reaching a duration of analgesia between 24 hours and 35 hours. It is highly bound to plasma proteins. Between 60 and 90% circulates bound to proteins, mainly acid glycoprotein. Unlike morphine, it does not generate active metabolites after its liver biotransformation and does not accumulate in kidney failure, which allows its use in patients with chronic kidney disease or hemodialysis. It is inexpensive compared to other opioids. In addition to its action on opioid receptors, it reduces the re-uptake of serotonin and norepinephrine involved in acute and chronic pain processes. It also exerts antagonistic activity at NMDA glutamatergic receptors. Glutamate is the main excitatory amino acid of the central nervous system and participates in the processes of nociceptive transmission at the spinal level. Its action on pain pathways is mainly mediated through ionotropic receptors (AMPA, NMDA and Kainic) involved in the generation and maintenance of states of hyperalgesia (exacerbated response to noxious stimulus) and allodynia (decreased pain threshold). These properties give it potential effectiveness in relieving neuropathic pain, also showing good results in the treatment of chronic pain and cancer pain.

Adequate control of postoperative pain is a relevant issue in cardiac surgery. Poorly treated acute pain can produce serious deleterious effects, namely; activation of the sympathetic system, tachycardia, arrhythmias and ischemia due to increased myocardial oxygen consumption. Pulmonary adverse effects (atelectasis and pneumonia), gastrointestinal (ileus), musculoskeletal (muscle weakness), endocrine (hypoglycemia) and psychological (depression). The presence of these complications delays and makes recovery difficult. With current techniques, incidences of acute pain between 30 and 75% are reported, with greater intensity during the first 2 days. Patients with high levels of postoperative pain have 3.5 times the risk of chronic pain and their inadequate treatment can lead to chronic or neuropathic pain that is difficult to manage . The incidence of chronic pain after cardiac surgery can reach up to 30-40% of patients during the first year.

In this scenario, the methadone use could confer certain advantages. Its long half-life would allow the establishment of simplified dosage schedules with less variability in plasma levels between doses than with the usual management that considers fentanyl or morphine in intermittent boluses. Its pharmacokinetics allow its administration in one dose per day, regardless of the need and cost of a continuous infusion pump. Methadone could reduce the incidence of chronic pain by optimizing acute pain control and its anti-NMDA activity. Finally, cardioprotective properties have been described.

Despite being a relatively old drug, the use of methadone as an alternative to short-acting opioids (fentanyl or morphine) in cardiac surgery is relatively recent. Few studies have been published with the use of intraoperative methadone in cardiac surgery and two report an adequate clinical effect with positive results. Although the presence of an adequate postoperative clinical effect suggests that exposure to cardiac surgery with cardiopulmonary bypass alone does not produce a significant change in postoperative methadone concentrations, the actual pharmacokinetic behavior of methadone in these circumstances is unknown. To date, there are no pharmacokinetic or pharmacodynamic studies that provide guidance on how to dose and adjust the dose of methadone in these patients.

• Study Type: Observational
• Enrollment (Anticipated): 30

Contacts and Locations

• Study Contact: Name: Wilbaldo Salas, MD; Phone Number: +56962061109; Email: wisalas@uc.cl
• Study Contact Backup: Name: Juan Cristobal Pedemonte, MD; Email: jcpedemo@uc.cl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 43 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Adult Patients who undergo cardiac surgery whith cardiopulmonary bypass.

Description

Inclusion Criteria:

• Patients between 45 and 75 years old who undergo surgery of coronary bypass with CPB, univalvular replacement, bivalvular or coronary bypass plus univalvular on a scheduled basis at the UC-Christus Clinical Hospital (HCUC) and that have ASA II-III classification.

Exclusion Criteria:

• BMI> 35, history of chronic liver damage, kidney damage with estimated creatinine clearance <60 ml / min, severe ventricular dysfunction (EF <30% or severe dysfunction in ventriculography), recent cerebrovascular accident (CVA) or sequelae, endocarditis, use of intraoperative ultrafiltration or methadone in the previous 36 hours.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Methadone Group; adult patients undergoing cardiac surgery with extracorporeal circulation	Drug: Methadone; Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak Plasma Concentration (Cmax)	Calculate maximum plasma concentration (Cmax) Methadone plasma levels measured with high pressure fluid (HPLC) after a single bolus of Methadone in enrolled adult Adults Undergoing Cardiac Surgery With Extracorporeal Circulation	Time Frame: 0, 5-10, 30, 60, 120, 240 minutes of operation of the CPB and 12 or 24 hours of CPB]
Describe the change of the levels of methadone plasmatic levels (ng/mL) measured by high pressure liquid chromatography (HPLC)	Change of the plasmatic levels of Methadone [ Time Frame: The concentrations will be measured in time: 0, 5-10, 30, 60, 120, 240 minutes of operation of the CPB and 12 or 24 hours of CPB]	Time Frame: 0, 5-10, 30, 60, 120, 240 minutes of operation of the CPB and 12 or 24 hours of CPB]

Collaborators and Investigators

• Sponsor: Pontificia Universidad Catolica de Chile
• Investigators: Principal Investigator: Wilbaldo Salas, MD, Pontificia Universidad Catolica de Chile

Publications and helpful links

General Publications

• Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000 Mar;44(3):261-73. doi: 10.1034/j.1399-6576.2000.440308.x.
• Starkey ES, Sammons HM. Practical pharmacokinetics: what do you really need to know? Arch Dis Child Educ Pract Ed. 2015 Feb;100(1):37-43. doi: 10.1136/archdischild-2013-304555. Epub 2014 Aug 13.
• Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Marymont JH, Shear T, Parikh KN, Patel SS, Gupta DK. Intraoperative Methadone for the Prevention of Postoperative Pain: A Randomized, Double-blinded Clinical Trial in Cardiac Surgical Patients. Anesthesiology. 2015 May;122(5):1112-22. doi: 10.1097/ALN.0000000000000633.

Study record dates

Study Major Dates

• Study Start (Anticipated): October 2, 2021
• Primary Completion (Anticipated): December 31, 2022
• Study Completion (Anticipated): April 1, 2023

Study Registration Dates

• First Submitted: September 29, 2021
• First Submitted That Met QC Criteria: September 29, 2021
• First Posted (Actual): October 12, 2021

Study Record Updates

• Last Update Posted (Actual): October 12, 2021
• Last Update Submitted That Met QC Criteria: September 29, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Keywords: extracorporeal circulation; pharmakinetics
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Respiratory System Agents; Antitussive Agents; Methadone
• Other Study ID Numbers: 200323005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No